

30 November 2007

SELECT VACCINES GRANTED AUSTRALIAN PATENT FOR ANTIVIRAL COMPOUNDS

Select Vaccines Ltd (ASX: SLT) today announced that it has been granted a key Australian patent over the Company's antiviral compounds. This patent is part of a wider Patent Cooperation Treaty (PCT) application (dated 30th January, 2003) that is still pending in other major territories.

The patent covers the use of a particular class of compounds that inhibit the replication of Picornaviruses. The clinical applications are far-reaching because these viruses cause a wide range of illnesses, from the common cold to meningitis and myocarditis.

"The protection and expansion of our intellectual property is a high priority at Select Vaccines, so the granting of this first patent on our antiviral compounds is an important step," said Martin Soust, CEO.

"It is also timely," he added, "as the prestigious Journal of Virology has just accepted for publication a scientific paper on the mechanism of action of these compounds."

FOR EDITORS:

The scientific paper referred to here is entitled "Amiloride Derivatives Inhibit Coxsackievirus B3 RNA Replication". Once published, it may be purchased and read online via the Journal of Virology website <http://jvi.asm.org>.

About Select Vaccines Limited

Select Vaccines Limited (ASX: SLT) is focused on the development of products targeting infectious diseases of global importance. The Company's Virus-Like Particle (VLP) vaccine technology provides a platform that can deliver a range of vaccine candidates and offers significant potential advantages over existing VLP technologies. Select Vaccines' lead products are an influenza vaccine and a hepatitis C vaccine. Both of these vaccines are in pre-clinical testing. Select Vaccines' principal research activities are undertaken at Melbourne's Burnet Institute, Australia's leading research institute in the field of infectious diseases caused by viruses and other agents.

Further information can be found at www.selectvaccines.com.au

CONTACTS:

Company	Media & Investor Relations
Martin Soust, Managing Director	Fay Weston – Talk Biotech
T: +61 (0)3 9529 8788	T: +61 (0)422 206036
E: martin@selectvaccines.com.au	E: fayweston@talkbiotech.com.au

ABN 25 062 063 692

Suite 15, 545 St Kilda Rd
Melbourne Victoria 3004 Australia

Telephone +613 9529 8788 Facsimile +613 9529 2622
www.selectvaccines.com.au